» Articles » PMID: 20737570

Genetic Variants in One-carbon Metabolism-related Genes Contribute to NSCLC Prognosis in a Chinese Population

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2010 Aug 26
PMID 20737570
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: One-carbon metabolism plays a critical role in DNA methylation and DNA synthesis. Variants of genes involved in one-carbon metabolism may result in aberrant methylation and/or DNA synthesis inhibition, and ultimately modulate the initiation and progression of tumors. In this study, the authors hypothesized that polymorphisms in one-carbon metabolism-related genes may contribute to the prognosis of nonsmall cell lung cancer (NSCLC).

Methods: The authors screened 57 potentially functional single nucleotide polymorphisms (SNPs) from 11 candidate genes involved in one-carbon metabolism and genotyped them in a cohort of 568 NSCLC patients by using Illumina Golden Gate platform. The Kaplan-Meier method with log-rank test and Cox proportional hazards model were used for survival analyses.

Results: Variant alleles were significantly associated with favorable survivals of NSCLC for MTR rs3768160 A>G (allelic hazards ratio [HR], 0.78; 95% confidence interval [CI], 0.62-0.98), MTRR rs2966952 G>A (allelic HR, 0.84; 95% CI, 0.71-0.99) and DHFR rs1650697 G>A (allelic HR, 0.83; 95% CI, 0.70-0.99) and with unfavorable prognosis for MTHFD1 rs1950902 G>A with borderline significance (allelic HR, 1.18; 95% CI, 0.99-1.40). In addition, the combined genotypes of these four SNPs showed a locus-dosage effect on NSCLC survival (P(trend) = 6.9 × 10(-5) ). In the final multivariate Cox regression model, combined genotypes based on 3 categories may be an independent prognostic factor for NSCLC with adjusted trend HR of 0.78 (95% CI, 0.66-0.92).

Conclusion: Genetic variants in one-carbon metabolism pathway may be candidate biomarkers for NSCLC prognosis.

Citing Articles

Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment.

Zhou L, Li Q, Xu J, Wang S, Song Z, Chen X Neurooncol Adv. 2023; 5(1):vdac181.

PMID: 36879663 PMC: 9985165. DOI: 10.1093/noajnl/vdac181.


GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.

Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T Sci Rep. 2020; 10(1):8435.

PMID: 32439996 PMC: 7242340. DOI: 10.1038/s41598-020-65463-6.


Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.

Hayano A, Takashima Y, Yamanaka R Int J Clin Oncol. 2019; 24(9):1020-1029.

PMID: 30993483 DOI: 10.1007/s10147-019-01451-9.


Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients.

Chen K, Liu H, Liu Z, Luo S, Patz Jr E, Moorman P Int J Cancer. 2019; 145(3):621-631.

PMID: 30650190 PMC: 6828159. DOI: 10.1002/ijc.32128.


Methylenetetrahydrofolate Dehydrogenase 1 Silencing Expedites the Apoptosis of Non-Small Cell Lung Cancer Cells via Modulating DNA Methylation.

Ding K, Jiang J, Chen L, Xu X Med Sci Monit. 2018; 24:7499-7507.

PMID: 30343310 PMC: 6206813. DOI: 10.12659/MSM.910265.